English

Ultimovacs ASA

ESEF

Report (type unavailable) · filed 2025-05-08

Annual consolidated revenue for 2024: about NOK 0, using the latest reported figures. The previous period, 2023, was about NOK 0.

Inspect reported changes Compare with another company Historical disclosures Segments

Watchlist

Latest fiscal year

Revenue

0 NOK

2024 · NOK

Exact inputs and evidence

Revenue: 0 NOK Source

Operating cash flow

-163 million NOK

2024 · NOK

Exact inputs and evidence

Operating Cash Flow: -163404000 NOK Source

Free cash flow

-163 million NOK

2024 · NOK

Exact inputs and evidence

Operating Cash Flow: -163404000 NOK Source
Capital Expenditure: 17000 NOK Source

Cash and cash equivalents: 107 million NOK 2024-12-31 Source
Exact value

107371000 NOK
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-05-08.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2024-12-31
Operating income: 5 of 11 periods available· newest 2024-12-31
Net income: 3 of 11 periods available· newest 2024-12-31
Operating cash flow: 5 of 11 periods available· newest 2024-12-31
Capital expenditure: 5 of 11 periods available· newest 2024-12-31
Total assets: 5 of 11 periods available· newest 2024-12-31
Total liabilities: 5 of 11 periods available· newest 2024-12-31
Current assets: 5 of 11 periods available· newest 2024-12-31
Current liabilities: 5 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
NOK 0

Prior period

NOK 0

2023-01-01 – 2023-12-31
Current period

NOK 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 0 = 0 NOK

0 NOK · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 NOK · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Ultimovacs ASA · 2024-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Year-over-year change in Revenue: 0 NOK Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17243036 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 Input fundies:Revenue: 0 NOK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17243471 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0
The citation records this snapshot. The page link may show a newer release later.
Net income
−NOK 11.82 million

Prior period

−NOK 189.24 million

2023-01-01 – 2023-12-31
Current period

−NOK 201.06 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-201061000 − -189239000 = -11822000 NOK

-189239000 NOK · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-201061000 NOK · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Ultimovacs ASA · 2024-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Year-over-year change in Net income: -11822000 NOK Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -201061000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17268193 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 Input fundies:NetIncome: -189239000 NOK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17268710 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+NOK 26.42 million

Prior period

−NOK 189.83 million

2023-01-01 – 2023-12-31
Current period

−NOK 163.4 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-163404000 − -189827000 = 26423000 NOK

-189827000 NOK · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-163404000 NOK · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Ultimovacs ASA · 2024-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Year-over-year change in Operating cash flow: 26423000 NOK Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -163404000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17394638 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 Input fundies:OperatingCashFlow: -189827000 NOK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17395155 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-32%

Prior period

NOK 25,000

2023-01-01 – 2023-12-31
Current period

NOK 17,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

17000 − 25000 = -8000 NOK

25000 NOK · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
17000 NOK · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Ultimovacs ASA · 2024-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Year-over-year change in Capital expenditure: -8000 NOK Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 17000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17397573 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 Input fundies:CapitalExpenditure: 25000 NOK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17398081 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue NOK 0
Operating costs Derived NOK 223.74 million
Operating income −NOK 223.74 million
Tax, interest and other Derived −NOK 22.68 million
Net income −NOK 201.06 million

Cash

Operating cash flow −NOK 163.4 million
Capital expenditure NOK 17,000
Free cash flow Derived −NOK 163.42 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	124146000 Derived	-124146000	Unavailable	Unavailable	-108505000 Derived	Source 2020-01-01 – 2020-12-31: 0 NOK Inspect Revenue Open source 2020-01-01 – 2020-12-31: -124146000 NOK Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -108223000 NOK Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 282000 NOK Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	163832000 Derived	-163832000	Unavailable	Unavailable	-125913000 Derived	Source 2021-01-01 – 2021-12-31: 0 NOK Inspect Revenue Open source 2021-01-01 – 2021-12-31: -163832000 NOK Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -125828000 NOK Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 85000 NOK Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	183631000 Derived	-183631000	-15839000 Derived	-167792000	-167890000 Derived	Source 2022-01-01 – 2022-12-31: 0 NOK Inspect Revenue Open source 2022-01-01 – 2022-12-31: -183631000 NOK Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -167792000 NOK Inspect Net Income Open source 2022-01-01 – 2022-12-31: -167695000 NOK Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 195000 NOK Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	215736000 Derived	-215736000	-26497000 Derived	-189239000	-189852000 Derived	Source 2023-01-01 – 2023-12-31: 0 NOK Inspect Revenue Open source 2023-01-01 – 2023-12-31: -215736000 NOK Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -189239000 NOK Inspect Net Income Open source 2023-01-01 – 2023-12-31: -189827000 NOK Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 25000 NOK Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	223744000 Derived	-223744000	-22683000 Derived	-201061000	-163421000 Derived	Source 2024-01-01 – 2024-12-31: 0 NOK Inspect Revenue Open source 2024-01-01 – 2024-12-31: -223744000 NOK Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -201061000 NOK Inspect Net Income Open source 2024-01-01 – 2024-12-31: -163404000 NOK Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 17000 NOK Inspect Capital Expenditure Open source

Amounts are exact, in NOK.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

NOK 0 2024

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20202020-12-31	Revenue	Revenue: 0 Open source
20212021-12-31	Revenue	Revenue: 0 Open source
20222022-12-31	Revenue	Revenue: 0 Open source
20232023-12-31	Revenue	Revenue: 0 Open source
20242024-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -124146000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -163832000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -183631000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -215736000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -223744000 Open source Revenue: 0 Open source
2020-12-31	Net margin	Not reported	Revenue: 0 Open source
2021-12-31	Net margin	Not reported	Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -167792000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	Not reported	Net Income: -189239000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	Not reported	Net Income: -201061000 Open source Revenue: 0 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -108223000 Open source Capital Expenditure: 282000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -125828000 Open source Capital Expenditure: 85000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -167695000 Open source Capital Expenditure: 195000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -189827000 Open source Capital Expenditure: 25000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -163404000 Open source Capital Expenditure: 17000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

NOK -163.4M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(NOK)	Source evidence
20202020-12-31	Operating cash flow	-108223000	Operating Cash Flow: -108223000 Open source
20212021-12-31	Operating cash flow	-125828000	Operating Cash Flow: -125828000 Open source
20222022-12-31	Operating cash flow	-167695000	Operating Cash Flow: -167695000 Open source
20232023-12-31	Operating cash flow	-189827000	Operating Cash Flow: -189827000 Open source
20242024-12-31	Operating cash flow	-163404000	Operating Cash Flow: -163404000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

NOK -163.4M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(NOK)	Source evidence
20202020-12-31	Free cash flow	-108505000	Operating Cash Flow: -108223000 Open source Capital Expenditure: 282000 Open source
20212021-12-31	Free cash flow	-125913000	Operating Cash Flow: -125828000 Open source Capital Expenditure: 85000 Open source
20222022-12-31	Free cash flow	-167890000	Operating Cash Flow: -167695000 Open source Capital Expenditure: 195000 Open source
20232023-12-31	Free cash flow	-189852000	Operating Cash Flow: -189827000 Open source Capital Expenditure: 25000 Open source
20242024-12-31	Free cash flow	-163421000	Operating Cash Flow: -163404000 Open source Capital Expenditure: 17000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

28.6% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	7.8%	Total Liabilities: 41337000 Open source Total Assets: 529717000 Open source
20212021-12-31	Liabilities / assets	9.5%	Total Liabilities: 62384000 Open source Total Assets: 655537000 Open source
20222022-12-31	Liabilities / assets	11.8%	Total Liabilities: 60321000 Open source Total Assets: 509672000 Open source
20232023-12-31	Liabilities / assets	20%	Total Liabilities: 69648000 Open source Total Assets: 349039000 Open source
20242024-12-31	Liabilities / assets	28.6%	Total Liabilities: 33194000 Open source Total Assets: 115863000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.62× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	16.36×	Current Assets: 449363000 Open source Current Liabilities: 27467000 Open source
20212021-12-31	Current assets / current liabilities	11.44×	Current Assets: 582255000 Open source Current Liabilities: 50897000 Open source
20222022-12-31	Current assets / current liabilities	9.49×	Current Assets: 435579000 Open source Current Liabilities: 45907000 Open source
20232023-12-31	Current assets / current liabilities	4.85×	Current Assets: 272117000 Open source Current Liabilities: 56109000 Open source
20242024-12-31	Current assets / current liabilities	3.62×	Current Assets: 113847000 Open source Current Liabilities: 31482000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	−NOK 108.22 million Exact value Exact value: -108223000 NOK 2020-01-01 – 2020-12-31: -108223000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ultimovacs ASA · 2020-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Operating Cash Flow: -108223000 NOK Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -108223000 NOK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2021-12-31/ESEF/NO/0/UltimovacsASA-2021-12-31-en.zip#37420116 Filing: 254900B4VALJZR9TL744-2021-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	NOK 282,000 Exact value Exact value: 282000 NOK 2020-01-01 – 2020-12-31: 282000 NOK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ultimovacs ASA · 2020-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Capital Expenditure: 282000 NOK Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=NOK&dimensions= Input fundies:CapitalExpenditure: 282000 NOK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2021-12-31/ESEF/NO/0/UltimovacsASA-2021-12-31-en.zip#37421164 Filing: 254900B4VALJZR9TL744-2021-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 108.51 million Calculation and evidence -108223000 − 282000 NOK Exact free cash flow: -108505000 NOK 2020-01-01 – 2020-12-31: -108223000 NOK · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 282000 NOK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ultimovacs ASA · 2020-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Free cash flow: -108505000 NOK Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -108223000 NOK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2021-12-31/ESEF/NO/0/UltimovacsASA-2021-12-31-en.zip#37420116 Filing: 254900B4VALJZR9TL744-2021-12-31-ESEF-NO-0 Input fundies:CapitalExpenditure: 282000 NOK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2021-12-31/ESEF/NO/0/UltimovacsASA-2021-12-31-en.zip#37421164 Filing: 254900B4VALJZR9TL744-2021-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	−NOK 125.83 million Exact value Exact value: -125828000 NOK 2021-01-01 – 2021-12-31: -125828000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ultimovacs ASA · 2021-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Operating Cash Flow: -125828000 NOK Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -125828000 NOK (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2022-12-31/ESEF/NO/0/UltimovacsASA-2022-12-31-en.zip#40443724 Filing: 254900B4VALJZR9TL744-2022-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	NOK 85,000 Exact value Exact value: 85000 NOK 2021-01-01 – 2021-12-31: 85000 NOK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ultimovacs ASA · 2021-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Capital Expenditure: 85000 NOK Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=NOK&dimensions= Input fundies:CapitalExpenditure: 85000 NOK (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2022-12-31/ESEF/NO/0/UltimovacsASA-2022-12-31-en.zip#40444676 Filing: 254900B4VALJZR9TL744-2022-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 125.91 million Calculation and evidence -125828000 − 85000 NOK Exact free cash flow: -125913000 NOK 2021-01-01 – 2021-12-31: -125828000 NOK · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 85000 NOK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ultimovacs ASA · 2021-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Free cash flow: -125913000 NOK Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -125828000 NOK (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2022-12-31/ESEF/NO/0/UltimovacsASA-2022-12-31-en.zip#40443724 Filing: 254900B4VALJZR9TL744-2022-12-31-ESEF-NO-0 Input fundies:CapitalExpenditure: 85000 NOK (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2022-12-31/ESEF/NO/0/UltimovacsASA-2022-12-31-en.zip#40444676 Filing: 254900B4VALJZR9TL744-2022-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−NOK 167.79 million Exact value Exact value: -167792000 NOK 2022-01-01 – 2022-12-31: -167792000 NOK Inspect Net Income Open source Share or cite Citation for Net Income · Ultimovacs ASA · 2022-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Net Income: -167792000 NOK Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=NOK&dimensions= Input fundies:NetIncome: -167792000 NOK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2023-12-31/ESEF/NO/0/UltimovacsASA-2023-12-31-en.zip#36504225 Filing: 254900B4VALJZR9TL744-2023-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 167.7 million Exact value Exact value: -167695000 NOK 2022-01-01 – 2022-12-31: -167695000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ultimovacs ASA · 2022-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Operating Cash Flow: -167695000 NOK Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -167695000 NOK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2023-12-31/ESEF/NO/0/UltimovacsASA-2023-12-31-en.zip#36573033 Filing: 254900B4VALJZR9TL744-2023-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	NOK 195,000 Exact value Exact value: 195000 NOK 2022-01-01 – 2022-12-31: 195000 NOK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ultimovacs ASA · 2022-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Capital Expenditure: 195000 NOK Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=NOK&dimensions= Input fundies:CapitalExpenditure: 195000 NOK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2023-12-31/ESEF/NO/0/UltimovacsASA-2023-12-31-en.zip#36573966 Filing: 254900B4VALJZR9TL744-2023-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 167.89 million Calculation and evidence -167695000 − 195000 NOK Exact free cash flow: -167890000 NOK 2022-01-01 – 2022-12-31: -167695000 NOK · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 195000 NOK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ultimovacs ASA · 2022-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Free cash flow: -167890000 NOK Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -167695000 NOK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2023-12-31/ESEF/NO/0/UltimovacsASA-2023-12-31-en.zip#36573033 Filing: 254900B4VALJZR9TL744-2023-12-31-ESEF-NO-0 Input fundies:CapitalExpenditure: 195000 NOK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2023-12-31/ESEF/NO/0/UltimovacsASA-2023-12-31-en.zip#36573966 Filing: 254900B4VALJZR9TL744-2023-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−NOK 189.24 million Exact value Exact value: -189239000 NOK 2023-01-01 – 2023-12-31: -189239000 NOK Inspect Net Income Open source Share or cite Citation for Net Income · Ultimovacs ASA · 2023-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Net Income: -189239000 NOK Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=NOK&dimensions= Input fundies:NetIncome: -189239000 NOK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17268710 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 189.83 million Exact value Exact value: -189827000 NOK 2023-01-01 – 2023-12-31: -189827000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ultimovacs ASA · 2023-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Operating Cash Flow: -189827000 NOK Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -189827000 NOK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17395155 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	NOK 25,000 Exact value Exact value: 25000 NOK 2023-01-01 – 2023-12-31: 25000 NOK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ultimovacs ASA · 2023-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Capital Expenditure: 25000 NOK Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=NOK&dimensions= Input fundies:CapitalExpenditure: 25000 NOK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17398081 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 189.85 million Calculation and evidence -189827000 − 25000 NOK Exact free cash flow: -189852000 NOK 2023-01-01 – 2023-12-31: -189827000 NOK · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 25000 NOK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ultimovacs ASA · 2023-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Free cash flow: -189852000 NOK Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -189827000 NOK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17395155 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 Input fundies:CapitalExpenditure: 25000 NOK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17398081 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−NOK 201.06 million Exact value Exact value: -201061000 NOK 2024-01-01 – 2024-12-31: -201061000 NOK Inspect Net Income Open source Share or cite Citation for Net Income · Ultimovacs ASA · 2024-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Net Income: -201061000 NOK Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=NOK&dimensions= Input fundies:NetIncome: -201061000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17268193 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 163.4 million Exact value Exact value: -163404000 NOK 2024-01-01 – 2024-12-31: -163404000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ultimovacs ASA · 2024-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Operating Cash Flow: -163404000 NOK Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -163404000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17394638 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	NOK 17,000 Exact value Exact value: 17000 NOK 2024-01-01 – 2024-12-31: 17000 NOK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ultimovacs ASA · 2024-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Capital Expenditure: 17000 NOK Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=NOK&dimensions= Input fundies:CapitalExpenditure: 17000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17397573 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 163.42 million Calculation and evidence -163404000 − 17000 NOK Exact free cash flow: -163421000 NOK 2024-01-01 – 2024-12-31: -163404000 NOK · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 17000 NOK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ultimovacs ASA · 2024-12-31 Ultimovacs ASA (esef:254900B4VALJZR9TL744) Free cash flow: -163421000 NOK Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/esef/254900B4VALJZR9TL744?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -163404000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17394638 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 Input fundies:CapitalExpenditure: 17000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/254900B4VALJZR9TL744/2024-12-31/ESEF/NO/0/254900B4VALJZR9TL744-2024-12-31-en.zip#17397573 Filing: 254900B4VALJZR9TL744-2024-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

4 filings · 264 latest values · 264 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 254900B4VALJZR9TL744, esef:254900B4VALJZR9TL744

Ultimovacs ASA

Latest fiscal year

Revenue

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation